Sankt Gertrauden-Krankenhaus GmbH
- Address
- Paretzer Strasse 12, Wilmersdorf, 10713 Berlin, Germany
Sankt Gertrauden-Krankenhaus GmbH
Sankt Gertrauden-Krankenhaus GmbH is a distinguished clinical research center specializing in advanced oncology and neurological research. The center demonstrates particular expertise in breast cancer therapeutics, conducting cutting-edge trials that investigate personalized treatment approaches and immunotherapy combinations for various breast cancer subtypes.
- Triple-negative breast cancer neoadjuvant and adjuvant immunotherapy trials
- HR+/HER2- early breast cancer personalized therapy optimization
- Primary progressive multiple sclerosis innovative treatment strategies
The institution's research portfolio reflects a commitment to precision medicine, particularly in hormone receptor-positive and triple-negative breast cancer populations. Their involvement in Phase III trials examining atezolizumab immunotherapy and ribociclib-based endocrine therapy demonstrates expertise in evaluating novel therapeutic combinations and biomarker-driven treatment strategies. Additionally, the center's participation in neurological studies targeting Bruton's tyrosine kinase inhibition for primary progressive multiple sclerosis showcases their multidisciplinary research capabilities and dedication to addressing challenging disease conditions with limited treatment options.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Sankt Gertrauden-Krankenhaus GmbH
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Adjuvant Dynamic Marker-Adjusted Personalized Therapy: Ribociclib Plus Endocrine Therapy Versus Chemotherapy in HR+/HER2- Early Breast Cancer | WSG Westdeutsche Studiengruppe GmbH | Phase III | Not Recruiting | Jul 2019 | — |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Atezolizumab | 1 | Unknown | 2018-06-13 | 2018-06-13 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.